AcelRx Pharmaceuticals, Inc. (ACRX)
(Delayed Data from NSDQ)
$3.66 USD
+0.10 (2.81%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.65 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Talphera, Inc. [ACRX]
Reports for Purchase
Showing records 21 - 40 ( 176 total )
Company: Talphera, Inc.
Industry: Medical - Drugs
Editorial Outlines DSUVIA''s Potential As a Key Component of Good Opioid Stewardship Practices
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Talphera, Inc.
Industry: Medical - Drugs
New Prospective Study Illustrates Multiple Advantages of DSUVIA Over Conventional Pain Management; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Talphera, Inc.
Industry: Medical - Drugs
3Q21 Recap; Lowell Acquisition Expands Pipeline; Moderating PT on Revised DSUVIA U.S. Sales Trajectory
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Talphera, Inc.
Industry: Medical - Drugs
Company: Talphera, Inc.
Industry: Medical - Drugs
2Q Recap: Cross-License Deal a Bright Spot, but DSUVIA Sales Need to Ramp Up; Reduce PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Talphera, Inc.
Industry: Medical - Drugs
Agreements Position DZUVEO for Success in Europe and Provides Two NDA-Ready Products to AcelRx; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Talphera, Inc.
Industry: Medical - Drugs
DSUVIA May Provide Analgesic Bridge For Sickle Cell Disease Patients Presenting at the Emergency Department
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Talphera, Inc.
Industry: Medical - Drugs
1Q21 Recap; We Begin to See The Light at The End of The COVID-19 Tunnel As DSUVIA Growth Strengthens; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Talphera, Inc.
Industry: Medical - Drugs
Phase 3 Pooled Analysis Provides Yet Further Evidence of Highly Positive Experiences With DSUVIA
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Talphera, Inc.
Industry: Medical - Drugs
4Q20 Recap: As Many Covid Restrictions Evaporate by Summer, Expect DSUVIA Ramp Beginning 2H21; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Talphera, Inc.
Industry: Medical - Drugs
Expecting DSUVIA Momentum to Continue As Positive Real World Experience Accumulates; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Talphera, Inc.
Industry: Medical - Drugs
Company: Talphera, Inc.
Industry: Medical - Drugs
Yet Another Publication Highlights DSUVIA As Superior to IV Opioids for Acute Perioperative Analgesia; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Talphera, Inc.
Industry: Medical - Drugs
DSUVIA''s Multiple Advantages Over IV Fentanyl Highlighted in Peer-Reviewed Journal; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Talphera, Inc.
Industry: Medical - Drugs
3Q20 Recap; DSUVIA Procurement Under Milestone C Expected to Begin in 4Q20; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Talphera, Inc.
Industry: Medical - Drugs
DSUVIA''s Clinical and Economic Advantages Elucidated in Two Separate Studies; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Talphera, Inc.
Industry: Medical - Drugs
Formulary Addition Paves the Way to Wider DSUVIA Adoption Across DoD; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Talphera, Inc.
Industry: Medical - Drugs
The Cleveland Clinic to Initiate a Study of DSUVIA; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Talphera, Inc.
Industry: Medical - Drugs
DSUVIA Showed Statistically Significant Advantages Over IV Opioids in Prospective Study; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Talphera, Inc.
Industry: Medical - Drugs
2Q20 Recap: We See Near-Term Opportunities as Pillars Supporting Long-Term Objectives; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E